Compare DHX & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DHX | PEPG |
|---|---|---|
| Founded | 1991 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.3M | 121.7M |
| IPO Year | 2007 | 2022 |
| Metric | DHX | PEPG |
|---|---|---|
| Price | $4.20 | $1.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $6.25 | ★ $11.17 |
| AVG Volume (30 Days) | 126.9K | ★ 1.1M |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.61 |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $127,826,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.52 | N/A |
| P/E Ratio | $102.25 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.44 | $1.01 |
| 52 Week High | $4.33 | $7.80 |
| Indicator | DHX | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 57.15 | 38.93 |
| Support Level | $3.49 | $1.47 |
| Resistance Level | $4.32 | $1.96 |
| Average True Range (ATR) | 0.25 | 0.22 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 59.40 | 1.09 |
DHI Group Inc is a provider of software products, online tools, and services that deliver career marketplaces to candidates and employers in the United States. The company operates through two reportable segments: ClearanceJobs and Dice. Its brands enable recruiters and hiring managers to search, match, and connect with skilled technologists, particularly in technology and active government security clearance, while professionals find job opportunities, job advice, and personalized data. ClearanceJobs connects security-cleared professionals with employers in a secure environment and supports engagement through messaging and live video. Dice, which generates maximum revenue, is a destination for technology and engineering talent, offering job postings across a range of technology roles.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.